Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-05212384 (PKI-587) in therapy-related and relapsed/refractory AML/MDS
2014-002752-50Phase 3Completed
- Sponsor
- Institut Curie
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of gedatolisib in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and Therapy-related leukemia (t-MN), sponsored by Institut Curie. Primary endpoint: Overall response rate (CR + CRu + PR). Started Jan 2015; status: completed.
02
Drugs
gedatolisib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)Therapy-related leukemia (t-MN)
Beyond the preview
Go deeper on 2014-002752-50.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002752-50.